CANCER, CHEMISTRY & CLINICALS:
WHERE INJECTABLE INNOVATION MEETS GLOBAL ASPIRATION

By: Sitav Elturan,
Singota Solutions



Singota® Solutions is a CDMO located in Bloomington, Indiana, USA that specializes in Parenteral, Early Phase Drug Development and Aseptic Filling projects.

If drug development were a crime thriller, oncology would be the cold case everyone's trying to solve - full of elusive biomarkers, late-night breakthroughs, and lives on the line. And right now, injectables are taking center stage. From monoclonal antibodies to peptides, the therapies reshaping patient outcomes are increasingly being delivered via vials or prefilled syringes.

As we gear up for the European Association for Cancer Research (EACR) 2025 meeting in Lisbon, Portugal, woman-owned Contract Development and Manufacturing Organization (CDMO) Singota Solutions is reflecting on the critical role injectables play in advancing cancer care. Each day, Singota diligently advances our client's injectable medicines from early development through fill/finish stages while providing global supply chain solutions. An increasing number of early-stage biopharmaceutical companies use Singota to advance their injectable oncology molecules through formulation and manufacturing fill/finish stages.

At Singota Solutions, injectable drug development is our mission. If you're heading to **#EACR2025**, stop by Singota's **Booth #131** to connect with our experts. But first, here's a look at the context behind Singota's presence at EACR. We touch on the science, the strategy, and why choosing the right CDMO partner - like Singota Solutions - can make all the difference.

The Oncology Injection Revolution

The global oncology pipeline now exceeds 2,000 assets, with many of these developed as injectables. Why? Because injectable formats offer superior bioavailability, targeted delivery, and controlled pharmacokinetics that oral forms often can't match.

Biologics like monoclonal antibodies, ADCs, cytokines, and cellular therapies depend on injectable delivery to overcome complex challenges. These therapies can block cancer's immune evasion, deliver targeted payloads, and improve patient outcomes. But formulation isn't simple: excipient compatibility, aggregation risk, shear sensitivity, and long-term stability must all be tightly managed. In oncology, there's no margin for error.

Formulation Matters, Especially for Oncology

A strong injectable formulation approach is foundational to success. Without a viable, scalable formulation, even the most promising molecule can stall in the progression to clinical trials.

Oncology injectables require special attention to API degradation, dosing volume tolerability, reconstitution ease, and safety risks, particularly for highly potent compounds. Clinical programs demand speed, precision, and flexibility. That's why developers turn to CDMO partners, like Singota Solutions, who understand early-phase drug development complexity. We can guide your molecule from preclinical stage development into Phase I and beyond.

Global Scale, Local Execution

Cancer knows no borders, which means drug development can't either. With innovation spanning continents, early-stage companies face a dilemma: how to find partners agile enough for collaboration but experienced enough for global execution? The answer is the "Goldilocks Zone" of CDMOs - not too big to be rigid, not too small to lack reach. The right partner brings regulatory fluency, supply chain resilience, and deep expertise in injectable development, fill/finish, and worldwide logistics.

GMP warehousing, cold-chain storage, and cross-region batch certification aren’t luxuries - they’re launch enablers. Meet Us at EACR 2025 to learn more! Injectables are advancing cancer care—and we’re here to accelerate that momentum.

With headquarters in Bloomington, Indiana and three EU-based facilities (in Switzerland in Balerna and Basel, and in Rovello Porro, Italy), Singota Solutions offers integrated support for global drug development. We are diligent, meticulous scientists, engineers, and problem-solvers focused on early-phase injectable programs.

Whether you're submitting your first IND or transferring production internationally, let’s talk at EACR. Because your science deserves a CDMO that delivers flexibility, precision, and partnership across borders.

See you at booth #131!

Singota Solutions is a US based CDMO in Bloomington, Indiana. Singota specializes in formulation development and aseptic fill finish for injectable projects. Once a formulation is established, Singota utilizes state of the art robotic filling technology and focuses on smaller batch size requirements. For more information, visit Singota.com to explore how Singota has established itself as a one-stop solution for all your developmental needs.

Contact **solutions@singota.com** to schedule a meeting with our business development team to further discuss your current or future projects.